These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 1423182)

  • 1. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin.
    Edmonson JH; Hartmann LC; Long HJ; Colon-Otero G; Fitch TR; Jefferies JA; Braich TA; Maples WJ
    Cancer; 1992 Nov; 70(10):2529-39. PubMed ID: 1423182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor.
    Rusthoven J; Levin L; Eisenhauer E; Mazurka J; Carmichael J; O'Connell G; Bryson P; Hirte H; Koski B
    J Natl Cancer Inst; 1991 Dec; 83(23):1748-53. PubMed ID: 1770554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study.
    Edmonson JH; Suman VJ; Dalton RJ; Bro WC; Gallenberg MM; Long HJ; Levitt R; Hatfield AK; Krook JE; Mailliard JA; Gerstner JB;
    Cancer Invest; 2001; 19(6):597-602. PubMed ID: 11486702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
    J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
    de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
    Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
    O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
    Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.
    Neidhart JA; Mangalik A; Stidley CA; Tebich SL; Sarmiento LE; Pfile JE; Oette DH; Oldham FB
    J Clin Oncol; 1992 Sep; 10(9):1460-9. PubMed ID: 1517789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.
    Frasci G; Perillo G; Comella G; Comella P; Polverino M; Menzella G; Persico G
    Cancer; 1995 Apr; 75(7):1578-85. PubMed ID: 8826913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
    Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
    Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
    Venturini M; Del Mastro L; Testore F; Danova M; Garrone O; Lanfranco C; Latini F; Sertoli MR; Lionetto R; Queirolo P; Ardizzoni A; Rosso R
    Cancer Chemother Pharmacol; 1996; 38(6):487-94. PubMed ID: 8823488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    de Wit R; Verweij J; Bontenbal M; Kruit WH; Seynaeve C; Schmitz PI; Stoter G
    J Natl Cancer Inst; 1996 Oct; 88(19):1393-8. PubMed ID: 8827017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.
    Reed E; Janik J; Bookman MA; Rothenberg M; Smith J; Young RC; Ozols RF; VanderMolen L; Kohn E; Jacob JL
    J Clin Oncol; 1993 Nov; 11(11):2118-26. PubMed ID: 8229126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies.
    McClay EF; Braly PD; Kirmani S; Plaxe SC; McClay ME; Wilgus L; Kim S; Howell SB
    Cancer; 1994 Jul; 74(2):664-9. PubMed ID: 8033046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
    Katakami N; Takada M; Negoro S; Ota K; Fujita J; Furuse K; Ariyoshi Y; Ikegami H; Fukuoka M
    Cancer; 1996 Jan; 77(1):63-70. PubMed ID: 8630941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The hematopoietic growth factor GM-CSF in chemotherapy for ovarian carcinoma].
    Biesma B; Willemse PH; Vellenga E; Limburg PC; Aalders JG; de Vries EG
    Ned Tijdschr Geneeskd; 1991 Mar; 135(10):420-4. PubMed ID: 2020314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.